Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Darekar

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2009
Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interactionOdette A Fahmi, Susan Hurst, David Plowchalk, et al.
Diabetes, Obesity & Metabolism|January 25, 2017
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise aloneSteven G Terra, Kristen Focht, Melanie Davies, et al.
BMJ Open|March 31, 2022
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) studyNeeta B Amin, Amanda Darekar, Quentin M Anstee, et al.
The Lancet. Gastroenterology & Hepatology|August 3, 2025
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy studyVincent Wai-Sun Wong, Neeta B Amin, Hirokazu Takahashi, et al.
British Journal of Clinical Pharmacology|February 19, 2008
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interactionKuresh A Youdim, Aref Zayed, Maurice Dickins, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2009
Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interactionOdette A Fahmi, Susan Hurst, David Plowchalk, et al.
Diabetes, Obesity & Metabolism|January 25, 2017
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise aloneSteven G Terra, Kristen Focht, Melanie Davies, et al.
BMJ Open|March 31, 2022
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) studyNeeta B Amin, Amanda Darekar, Quentin M Anstee, et al.
The Lancet. Gastroenterology & Hepatology|August 3, 2025
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy studyVincent Wai-Sun Wong, Neeta B Amin, Hirokazu Takahashi, et al.
British Journal of Clinical Pharmacology|February 19, 2008
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interactionKuresh A Youdim, Aref Zayed, Maurice Dickins, et al.
Pageof 3